Company Overview
Nanobiotix S.A. operates as a clinical-stage biotechnology entity dedicated to developing product candidates designed for the treatment of cancer and other unmet medical needs. The company functions within the healthcare sector, specifically inside the biotechnology industry, which focuses on the discovery, development, and commercialization of innovative biological therapeutics. This specific biotechnology firm currently maintains a market capitalization of $1.46B, reports trailing twelve-month revenue of $10.16M, and employs a workforce of 103 individuals. The combination of a $1.46B market cap with only $10.16M in annual revenue indicates that the company's valuation is driven primarily by the potential of its pipeline rather than current profitability, suggesting significant future growth expectations from the market. The scale of the operation, supported by 103 employees, reflects a lean organizational structure typical of early-stage biotech firms that rely heavily on intellectual property and research capabilities to generate value.
Financial Health
The company reported a revenue of $10.16M for the trailing twelve months, yet generated a net income of $-51,643,000 and an EBITDA of $-43,844,000. The substantial gap between the $10.16M in revenue and the negative $51.64M in net income reveals a cost structure where research, development, and operational expenses significantly outweigh current sales, which is characteristic of clinical-stage development. Free cash flow stands at $-17,269,250, indicating that the company is consuming cash to fund its operations and development activities, thereby limiting immediate financial flexibility for dividends or acquisitions. Gross margin is recorded at 100.0%, which reflects the accounting treatment of research and development costs as period expenses rather than cost of goods sold, while an operating margin of 3.1% and a profit margin of 0.0% highlight the ongoing operational losses despite high gross efficiency. Total cash on hand is $28.82M, which is less than the total debt of $51.24M, creating a net cash deficit position. The debt-to-equity ratio is listed as N/A, preventing a direct comparison of leverage against equity, but the absolute debt level relative to cash reserves suggests a leveraged balance sheet reliant on future financing or milestone payments. The current ratio is 0.63, indicating that the company's current assets are insufficient to cover its current liabilities, which points to potential short-term liquidity challenges. Return on equity is N/A due to the lack of positive retained earnings or equity base in the traditional sense for calculation, while return on assets is -41.6%, demonstrating that the company's assets are currently generating negative returns on the capital invested.
Valuation Assessment
The trailing P/E ratio is N/A because the company is not currently profitable, whereas the forward P/E is 97.57, implying that the market prices in significant anticipated earnings growth that has not yet materialized in historical data. The price-to-book ratio is -18.25, a negative figure that indicates the company's market value is priced well below its net asset value, often seen in biotech firms with intangible assets not fully captured on the balance sheet. The price-to-sales ratio is 143.99, suggesting that investors are willing to pay a high multiple relative to sales, reflecting confidence in the commercial potential of the lead product candidate NBTXR3. Additionally, the EV/EBITDA stands at -32.44, an alternative valuation metric that further underscores the speculative nature of the stock given the negative earnings before interest, taxes, depreciation, and amortization. The 52-week high is $41.89 and the 52-week low is $2.99, meaning the stock trades in a highly volatile range with a current price significantly elevated above the recent lows but still subject to substantial downward pressure from the low end. The beta is 0.57, indicating that the stock exhibits lower volatility relative to the broader market, moving less sharply than the overall index despite the high valuation multiples.
Growth & Income
Revenue growth year-over-year is 186.8%, demonstrating a massive expansion in top-line sales likely driven by regulatory approvals or commercial launches, while earnings growth is N/A due to the absence of positive historical earnings to compare. Since earnings growth cannot be measured against the prior period in a traditional sense, the revenue expansion stands as the primary driver of company progression, implying that profitability has not yet been achieved to support earnings per share growth. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, which aligns with the strategy of reinvesting all available resources into research and development. The overall growth and income profile is characterized by aggressive revenue expansion coupled with zero current income distribution, prioritizing capital allocation toward advancing clinical candidates over shareholder returns.